M&A Deal Summary

Ampersand Capital Partners Acquires iuvo

On September 28, 2022, growth capital firm Ampersand Capital Partners acquired life science company iuvo

Acquisition Highlights
  • This is Ampersand Capital Partners’ 37th transaction in the Life Science sector.
  • This is Ampersand Capital Partners’ 64th transaction in the United States.
  • This is Ampersand Capital Partners’ 1st transaction in New York.

M&A Deal Summary
Date 2022-09-28
Target iuvo
Sector Life Science
Buyer(s) Ampersand Capital Partners
Deal Type Buyout (LBO, MBO, MBI)

Target

iuvo

Rush, New York, United States
iuvo is a partner research organization (PRO) serving the medical device and pharmaceutical industries. iuvo offers technical and regulatory consulting services, contract laboratory services, and contract sterilization out of its two locations, in Rush, New York, and Erie, Pennsylvania. iuvo was founded in 1978 and is based in Rush, New York.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1988
PE ASSETS 2.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.

DEAL STATS #
Overall 75 of 82
Sector (Life Science) 37 of 42
Type (Buyout (LBO, MBO, MBI)) 23 of 23
State (New York) 1 of 1
Country (United States) 64 of 67
Year (2022) 10 of 10
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-09-07 AcuraBio

Darra, Australia

AcuraBio provides recombinant proteins and vaccines, and complex live biotherapeutic products to customers on the leading edge in emerging therapeutics. AcuraBio is based in Darra, Australia.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-10-03 GenDx

Utrecht, Netherlands

GenDx is a Dutch company specializing in Molecular Diagnostics, focused on the development, production, and sales of innovative assays and analysis software for transplantation and companion diagnostics. GenDx specializes in HLA sequencing-based typing strategies and offers reagents and software for both Sanger and NGS approaches. GenDx was founded in 2005 and is based in Utrecht, Netherlands.

Sell €135M
Mergr

Product

Company

Legal